LIFEMD INC

LIFEMD INC (LFMD)

$2.1358

-0.04

(-2.03%)

Live

Insights on LIFEMD INC

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 87.62M → 33.12M (in $), with an average decrease of 62.2% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -40.58M → -4.00M (in $), with an average increase of 912.5% per quarter

  • Vs TXG

    In the last 1 year, LifeMD Inc has experienced a drawdown of -5.2%, however 10x Genomics Inc - Class A resisted the overall trend and outperformed by 5.0%

Performance

  • $2.14
    $2.17
    $2.14
    downward going graph

    0.0%

    Downside

    Day's Volatility :1.38%

    Upside

    1.38%

    downward going graph
  • $1.14
    $3.22
    $2.14
    downward going graph

    46.73%

    Downside

    52 Weeks Volatility :64.6%

    Upside

    33.54%

    downward going graph

Returns

PeriodLIFEMD INCSector (Consumer Staples)Index (Russel 2000)
3 Months
22.47%
1.9%
-6.7%
6 Months
-10.29%
-4.9%
-6.2%
1 Year
-3.11%
-2.1%
-6.3%
3 Years
45.33%
24.0%
26.9%

Highlights

Market Capitalization
70.3M
Book Value
- $0.38
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-1.28
Wall Street Target Price
5.25
Profit Margin
-29.44%
Operating Margin TTM
-23.91%
Return On Assets TTM
-43.71%
Return On Equity TTM
-782.48%
Revenue TTM
123.1M
Revenue Per Share TTM
3.95
Quarterly Revenue Growth YOY
14.099999999999998%
Gross Profit TTM
100.4M
EBITDA
-28.2M
Diluted Eps TTM
-1.28
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.35
EPS Estimate Next Year
-0.25
EPS Estimate Current Quarter
-0.16
EPS Estimate Next Quarter
-0.14

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for LIFEMD INC(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 145.81%

Current $2.14
Target $5.25

Company Financials

FY17Y/Y Change
Revenue
5.1M
↓ 3.51%
Net Income
-1.2M
↑ 8.89%
Net Profit Margin
-23.86%
↓ 2.72%
FY18Y/Y Change
Revenue
8.3M
↑ 64.68%
Net Income
-1.2M
↑ 2.89%
Net Profit Margin
-14.91%
↑ 8.95%
FY19Y/Y Change
Revenue
12.5M
↑ 49.79%
Net Income
-3.1M
↑ 152.83%
Net Profit Margin
-25.16%
↓ 10.25%
FY20Y/Y Change
Revenue
37.3M
↑ 199.1%
Net Income
-58.6M
↑ 1769.4%
Net Profit Margin
-157.26%
↓ 132.1%
FY21Y/Y Change
Revenue
92.9M
↑ 149.04%
Net Income
-60.9M
↑ 3.84%
Net Profit Margin
-65.57%
↑ 91.69%
FY22Y/Y Change
Revenue
119.0M
↑ 28.16%
Net Income
-48.6M
↓ 20.13%
Net Profit Margin
-40.86%
↑ 24.71%
Q4 FY21Q/Q Change
Revenue
27.4M
↑ 9.9%
Net Income
-18.1M
↑ 26.18%
Net Profit Margin
-66.06%
↓ 8.52%
Q1 FY22Q/Q Change
Revenue
29.0M
↑ 5.93%
Net Income
-13.3M
↓ 26.57%
Net Profit Margin
-45.79%
↑ 20.27%
Q2 FY22Q/Q Change
Revenue
30.5M
↑ 4.87%
Net Income
-13.0M
↓ 2.11%
Net Profit Margin
-42.74%
↑ 3.05%
Q3 FY22Q/Q Change
Revenue
31.4M
↑ 3.13%
Net Income
-8.1M
↓ 38.1%
Net Profit Margin
-25.65%
↑ 17.09%
Q4 FY22Q/Q Change
Revenue
87.6M
↑ 178.94%
Net Income
-40.6M
↑ 403.63%
Net Profit Margin
-46.32%
↓ 20.67%
Q1 FY23Q/Q Change
Revenue
33.1M
↓ 62.19%
Net Income
-4.0M
↓ 90.12%
Net Profit Margin
-12.1%
↑ 34.22%
FY17Y/Y Change
Total Assets
1.3M
↑ 60.01%
Total Liabilities
641.0K
↓ 44.34%
FY18Y/Y Change
Total Assets
2.6M
↑ 107.0%
Total Liabilities
1.8M
↑ 180.26%
FY19Y/Y Change
Total Assets
3.4M
↑ 31.73%
Total Liabilities
4.6M
↑ 154.7%
FY20Y/Y Change
Total Assets
13.1M
↑ 278.79%
Total Liabilities
13.9M
↑ 203.26%
FY21Y/Y Change
Total Assets
49.9M
↑ 282.45%
Total Liabilities
24.1M
↑ 73.72%
FY22Y/Y Change
Total Assets
25.7M
↓ 48.59%
Total Liabilities
33.0M
↑ 36.79%
Q4 FY21Q/Q Change
Total Assets
49.9M
↑ 205.31%
Total Liabilities
24.1M
↓ 22.28%
Q1 FY22Q/Q Change
Total Assets
50.3M
↑ 0.74%
Total Liabilities
33.9M
↑ 40.79%
Q2 FY22Q/Q Change
Total Assets
38.0M
↓ 24.5%
Total Liabilities
31.2M
↓ 8.19%
Q3 FY22Q/Q Change
Total Assets
33.4M
↓ 12.14%
Total Liabilities
30.3M
↓ 2.81%
Q4 FY22Q/Q Change
Total Assets
25.7M
↓ 23.07%
Total Liabilities
33.0M
↑ 8.89%
Q1 FY23Q/Q Change
Total Assets
33.9M
↑ 31.96%
Total Liabilities
41.2M
↑ 25.05%
FY17Y/Y Change
Operating Cash Flow
-817.2K
↑ 100.34%
Investing Cash Flow
141.4K
↑ 0.0%
Financing Cash Flow
776.0K
↑ 117.08%
FY18Y/Y Change
Operating Cash Flow
-905.5K
↑ 10.81%
Investing Cash Flow
141.4K
↑ 0.0%
Financing Cash Flow
802.8K
↑ 3.45%
FY19Y/Y Change
Operating Cash Flow
251.4K
↓ 127.76%
Investing Cash Flow
-100.0K
↓ 170.7%
Financing Cash Flow
775.1K
↓ 3.45%
FY20Y/Y Change
Operating Cash Flow
-12.1M
↓ 4925.47%
Investing Cash Flow
-798.1K
↑ 698.14%
Financing Cash Flow
21.0M
↑ 2609.53%
FY21Y/Y Change
Operating Cash Flow
-33.1M
↑ 172.72%
Investing Cash Flow
-3.4M
↑ 326.28%
Financing Cash Flow
68.6M
↑ 226.81%
Q4 FY21Q/Q Change
Operating Cash Flow
-5.8M
↓ 21.47%
Investing Cash Flow
-1.6M
↑ 84.96%
Financing Cash Flow
39.3M
↑ 12769.63%
Q1 FY22Q/Q Change
Operating Cash Flow
-8.1M
↑ 38.88%
Investing Cash Flow
-7.4M
↑ 367.43%
Financing Cash Flow
-774.1K
↓ 101.97%
Q2 FY22Q/Q Change
Operating Cash Flow
-10.1M
↑ 24.82%
Investing Cash Flow
-2.5M
↓ 65.91%
Financing Cash Flow
-753.4K
↓ 2.67%
Q3 FY22Q/Q Change
Operating Cash Flow
-2.8M
↓ 72.51%
Investing Cash Flow
-2.2M
↓ 10.87%
Financing Cash Flow
-862.9K
↑ 14.53%
Q1 FY23Q/Q Change
Operating Cash Flow
-2.6M
↓ 87.03%
Investing Cash Flow
-1.8M
-
Financing Cash Flow
12.0M
↑ 3482.61%

Technicals Summary

Sell

Neutral

Buy

LIFEMD INC is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
LIFEMD INC
LIFEMD INC
38.85%
-10.29%
-3.11%
45.33%
83.35%
R1 RCM Inc
R1 RCM Inc
3.35%
77.46%
-25.2%
51.08%
100.5%
10X Genomics Inc
10X Genomics Inc
0.9%
36.78%
3.3%
-35.47%
0.25%
Veeva Systems Inc.
Veeva Systems Inc.
-8.07%
-13.07%
-2.81%
-24.42%
115.05%
GE HEALTHCARE TECHNOLOGIES INC.
GE HEALTHCARE TECHNOLOGIES INC.
-2.91%
29.66%
29.66%
29.66%
29.66%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
LIFEMD INC
LIFEMD INC
NA
NA
NA
-0.35
-7.82
-0.44
0.0
-0.38
R1 RCM Inc
R1 RCM Inc
128.18
NA
0.77
0.04
-0.06
0.04
0.0
6.5
10X Genomics Inc
10X Genomics Inc
NA
NA
NA
-1.42
-0.22
-0.11
0.0
6.91
Veeva Systems Inc.
Veeva Systems Inc.
54.08
54.08
1.27
4.18
0.15
0.07
0.0
23.48
GE HEALTHCARE TECHNOLOGIES INC.
GE HEALTHCARE TECHNOLOGIES INC.
21.37
21.37
NA
3.73
0.16
0.06
0.0
14.72
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
LIFEMD INC
LIFEMD INC
Buy
$70.3M
83.35%
NA
-29.44%
R1 RCM Inc
R1 RCM Inc
Buy
$6.7B
100.5%
128.18
-4.41%
10X Genomics Inc
10X Genomics Inc
Buy
$6.1B
0.25%
NA
-32.51%
Veeva Systems Inc.
Veeva Systems Inc.
Buy
$26.5B
115.05%
54.08
22.63%
GE HEALTHCARE TECHNOLOGIES INC.
GE HEALTHCARE TECHNOLOGIES INC.
Buy
$35.7B
29.66%
21.37
9.17%

Institutional Holdings

  • Royce & Associates, LP

    3.29%
  • B. Riley Financial Inc

    2.84%
  • Vanguard Group Inc

    2.18%
  • Shah Capital Management

    1.72%
  • BlackRock Inc

    1.30%
  • American Financial Group Inc

    1.05%

Corporate Announcements

  • LIFEMD INC Earnings

    LIFEMD INC’s price-to-earnings ratio stands at None

    Read More

Company Information

LifeMD, Inc. (formerly Conversion Labs) is a leading telehealth company that is transforming the healthcare landscape with direct-to-patient product and service offerings. LifeMD's telemedicine platform enables virtual access to affordable and convenient medical treatment from licensed providers and, when appropriate, prescription medications and over-the-counter products delivered directly to the patient's home.

Organization
LIFEMD INC
Employees
199
CEO
Mr. Justin Schreiber
Industry
Healthcare

FAQs